MHMark A. Hancock

Mark A. Hancock

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark A. Hancock has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characterization of endothelin-converting enzyme 1 as a key enzyme in the multienzyme Aβ degradation pathway

    by Irem Ulku, Fatima El Ansari, Mark A. Hancock, Hedi Zhou, Gael Cagnone, Jean-Sebastien Joyal, Teddy A. J. Fisher, Timothy E. Kennedy, Filip Liebsch, Gerhard Multhaup

    Altered β-amyloid (Aβ) homeostasis is a critical event triggering the shift from healthy aging to Alzheimer disease (AD) through the overproduction and impaired clearance of Aβ peptides. The Aβ-degrading enzymes (ADEs) are a collective group of proteases that normally promote clearance to counteract Aβ-induced neurodegeneration. We previously discovered that the beta-site amyloid precursor protein cleaving enzyme 1 is an atypical ADE that produces the nontoxic fragment Aβ34 by recognizing 40- or 42-residue-long Aβ peptides as substrates in vitro and in vivo. Here, we examined other known ADEs for their potential roles in degrading Aβ34, Aβ40, and Aβ42. By genetic, cellular, and pharmacological approaches, we identified and characterized endothelin-converting enzyme 1 (ECE1) in a human neuroblastoma cell line, human brain vascular pericytes, and primary rat cortical cultures as a major enzyme degrading Aβ34 but not Aβ40 or Aβ42. Notably, we found that ECE1 cleaves Aβ34, an indicator of amyloid clearance, to a unique and unusually stable Aβ20-34 fragment that has the potential to serve as a measurable biomarker. Biocomputational analyses from non-AD controls and individuals with AD pathology showed that the highest messenger ribonucleic acid (mRNA) levels of ECE1 expression were found in pericytes (i.e., cells within the brain microvasculature that are known to produce Aβ34) compared to other cell types. Given Aβ34 is an indicator for prodromal AD, we postulate that our collective findings (i.e., generation of Aβ34 and Aβ20-34 intermediates within the “amyloidolytic” degradation pathway) will generate a set of biomarkers to detect amyloid clearance activity in vivo.


  • Open Access

    Unveiling the molecular mechanisms of the type IX secretion system's response regulator: Structural and functional insights

    by Anshu Saran, Hey-Min Kim, Ireland Manning, Mark A Hancock, Claus Schmitz, Mariusz Madej, Jan Potempa, Maria Sola, Jean-François Trempe, Yongtao Zhu, et al.

    The type IX secretion system (T9SS) is a nanomachinery utilized by bacterial pathogens to facilitate infection. The system is regulated by a signaling cascade serving as its activation switch. A pivotal member in this cascade, the response regulator protein PorX, represents a promising drug target to prevent the secretion of virulence factors. Here, we provide a comprehensive characterization of PorX both in vitro and in vivo. First, our structural studies revealed PorX harbors a unique enzymatic effector domain, which, surprisingly, shares structural similarities with the alkaline phosphatase superfamily, involved in nucleotide and lipid signaling pathways. Importantly, such pathways have not been associated with the T9SS until now. Enzymatic characterization of PorX's effector domain revealed a zinc-dependent phosphodiesterase activity, with active site dimensions suitable to accommodate a large substrate. Unlike typical response regulators that dimerize via their receiver domain upon phosphorylation, we found that zinc can also induce conformational changes and promote PorX's dimerization via an unexpected interface. These findings suggest that PorX can serve as a cellular zinc sensor, broadening our understanding of its regulatory mechanisms. Despite the strict conservation of PorX in T9SS-utilizing bacteria, we demonstrate that PorX is essential for virulence factors secretion in Porphyromonas gingivalis and affects metabolic enzymes secretion in the nonpathogenic Flavobacterium johnsoniae, but not for the secretion of gliding adhesins. Overall, this study advances our structural and functional understanding of PorX, highlighting its potential as a druggable target for intervention strategies aimed at disrupting the T9SS and mitigating virulence in pathogenic species.


  • Open Access

    Inhibition of BACE1 affected both its Aβ producing and degrading activities and increased Aβ42 and Aβ40 levels at high-level BACE1 expression

    by Irem Ulku, Rocher Leung, Fritz Herre, Lina Walther, Adeola Shobo, Paul Saftig, Mark A. Hancock, Filip Liebsch, Gerhard Multhaup


  • Open Access

    Identification and characterization of calreticulin as a novel plasminogen receptor

    by Alamelu G. Bharadwaj, Gillian C. Okura, John W. Woods, Erica A. Allen, Victoria A. Miller, Emma Kempster, Mark A. Hancock, Shashi Gujar, Rimantas Slibinskas, David M. Waisman


  • Biophysical characterization as a tool to predict amyloidogenic and toxic properties of amyloid‐β42 peptides

    by Adeola Shobo, Alexander Röntgen, Mark A. Hancock, Gerhard Multhaup

    Amyloid‐β42 (Aβ42) peptides are central to the amyloid pathology in Alzheimer's disease (AD). As biological mimetics, properties of synthetic Aβ peptides usually vary between vendors and batches, thus impacting the reproducibility of experimental studies. Here, we tested recombinantly expressed Aβ42 (Asp1 to Ala42) against synthetic Aβ42 from different suppliers using matrix‐assisted laser desorption/ionization mass spectrometry (MALDI‐MS), circular dichroism (CD) spectroscopy, thioflavin T aggregation, surface plasmon resonance, and MTT cell viability assays. Overall, our recombinant Aβ42 provided a reproducible mimetic of desired properties. Across experimental approaches, the combined detection of Aβ42 dimers and random coil to β‐sheet transition only correlated with aggregation‐prone and cytotoxic peptides. Conclusively, combining MALDI‐MS with CD appears to provide a rapid, reliable means to predict the ‘bioactivity’ of Aβ42.


  • Open Access

    The amyloid-β1–42-oligomer interacting peptide D-AIP possesses favorable biostability, pharmacokinetics, and brain region distribution

    by Adeola Shobo, Nicholas James, Daniel Dai, Alexander Röntgen, Corbin Black, Jean-Robert Kwizera, Mark A. Hancock, Khanh Huy Bui, Gerhard Multhaup


  • Top Cited Papers
    Open Access

    Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination

    by Guido Veit, Ariel Roldan, Mark A. Hancock, Dillon F. Da Fonte, Haijin Xu, Maytham Hussein, Saul Frenkiel, Elias Matouk, Tony Velkov, Gergely L. Lukacs

    Based on its clinical benefits, Trikafta — the combination of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor), and the gating potentiator VX-770 (ivacaftor) — was FDA approved for treatment of patients with cystic fibrosis (CF) carrying deletion of phenylalanine at position 508 (F508del) of the CF transmembrane conductance regulator ( CFTR ) on at least 1 allele. Neither the mechanism of action of VX-445 nor the susceptibility of rare CF folding mutants to Trikafta are known. Here, we show that, in human bronchial epithelial cells, VX-445 synergistically restores F508del-CFTR processing in combination with type I or II correctors that target the nucleotide binding domain 1 (NBD1) membrane spanning domains (MSDs) interface and NBD2, respectively, consistent with a type III corrector mechanism. This inference was supported by the VX-445 binding to and unfolding suppression of the isolated F508del-NBD1 of CFTR. The VX-661 plus VX-445 treatment restored F508del-CFTR chloride channel function in the presence of VX-770 to approximately 62% of WT CFTR in homozygous nasal epithelia. Substantial rescue of rare misprocessing mutations (S13F, R31C, G85E, E92K, V520F, M1101K, and N1303K), confined to MSD1, MSD2, NBD1, and NBD2 of CFTR, was also observed in airway epithelia, suggesting an allosteric correction mechanism and the possible application of Trikafta for patients with rare misfolding mutants of CFTR.


  • Open Access

    Spt5 phosphorylation and the Rtf1 Plus3 domain promote Rtf1 function through distinct mechanisms

    by Jennifer J. Chen, Jean Mbogning, Mark A. Hancock, Dorsa Majdpour, Manan Madhok, Hassan Nassour, Juliana C. Dallagnol, Viviane Pagé, David Chatenet, Jason C. Tanny

    Rtf1 is a conserved RNA polymerase II (RNAPII) elongation factor that promotes co-transcriptional histone modification, RNAPII transcript elongation, and mRNA processing. Rtf1 function requires phosphorylation of Spt5, an essential RNAPII processivity factor. Spt5 is phosphorylated within its C-terminal domain (CTD) by cyclin-dependent kinase 9 (Cdk9), catalytic component of positive transcription elongation factor b (P-TEFb). Rtf1 recognizes phosphorylated Spt5 (pSpt5) through its Plus3 domain. Since Spt5 is a unique target of Cdk9, and Rtf1 is the only known pSpt5-binding factor, the Plus3/pSpt5 interaction is thought to be a key Cdk9-dependent event regulating RNAPII elongation. Here we dissect Rtf1 regulation by pSpt5 in the fission yeast Schizosaccharomyces pombe . We demonstrate that the Plus3 domain of Rtf1 (Prf1 in S. pombe ) and pSpt5 are functionally distinct, and that they act in parallel to promote Prf1 function. This alternate Plus3 domain function involves an interface that overlaps with the pSpt5 binding site and that can interact with single-stranded nucleic acid or with the Polymerase Associated Factor (PAF) Complex in vitro . We further show that the C-terminal region of Prf1, which also interacts with PAF, has a similar parallel function with pSpt5. Our results elucidate unexpected complexity underlying Cdk9-dependent pathways that regulate transcription elongation.

  • Top Cited Papers

    Structural basis for allosteric PARP-1 retention on DNA breaks

    by Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, Mark A. Hancock, Jamin D. Steffen, Ramya Billur, Zain M. Hannan, Andrew J. Wicks, Dragomir B. Krastev, Stephen J. Pettitt, et al.

    DNA death grip: Poly(ADP-ribose) polymerase–1 (PARP-1) binds to DNA breaks and recruits DNA repair components. Cancer-killing PARP-1 inhibitor (PARPi) compounds all block the same catalytic site but exhibit vastly different efficacy. Zandarashvili et al. investigated the molecular impact of PARPi binding to PARP-1 (see the Perspective by Slade and Eustermann). Different PARPi molecules perturb PARP-1 allostery in diverse manners: Some drive allostery to promote release of PARP-1 from DNA, and others drive allostery to promote retention. These insights help explain the different efficacies in the clinic and enable conversion of a pro-release, ineffective cancer-killing compound to a pro-retention, more effective PARPi. Science , this issue p. eaax6367 ; see also p. 30


  • Neurodegenerative Disease-Related Proteins within the Epidermal Layer of the Human Skin

    by S. Can Akerman, Shireen Hossain, Adeola Shobo, Yifei Zhong, Roland Jourdain, Mark A. Hancock, Kelly George, Lionel Breton, Gerhard Multhaup

    There is increasing evidence suggesting that amyloidogenic proteins might form deposits in non-neuronal tissues in neurodegenerative disorders such as Alzheimer’s or Parkinson’s diseases. However, the detection of these aggregation-prone proteins wit